| Page 17 | Aplastic Anemia and MDS International Foundation

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Author(s): 
Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ
Primary Author: 
Swords RT
Journal Title: 
Blood Cancer J
Original Publication Date: 
Feb 2017

No abastract available.

Bone Marrow Diseases: 

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis

Author(s): 
Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, Fei JP, Xu BL
Primary Author: 
Shou LH
Journal Title: 
PLoS One
Original Publication Date: 
Feb 2017

OBJECTIVES:

Bone Marrow Diseases: 

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Author(s): 
Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kula
Primary Author: 
Oliva EN
Journal Title: 
Lancet Haematol
Original Publication Date: 
Feb 2017

BACKGROUND:

Bone Marrow Diseases: 

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

Author(s): 
Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD
Primary Author: 
Prebet T
Journal Title: 
Oncotarget
Original Publication Date: 
Feb 2017

Bone Marrow Diseases: 

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

Author(s): 
Stahl M, Zeidan AM
Primary Author: 
Stahl M
Journal Title: 
Cancer
Original Publication Date: 
Feb 2017

Myelosysplastic syndromes (MDS) include a heterogeneous group of clonal myeloid neoplasms characterized by ineffective hematopoiesis leading to blood cytopenias and a variable risk of progression into acute myeloid leukemia (AML).

Bone Marrow Diseases: 

De-escalation empirical antibiotic therapy improved survival for patients with severe aplastic anemia treated with antithymocyte globulin.

Author(s): 
Fu R, Chen T, Song J, Wang G, Li L, Ruan E, Liu H, Wang Y, Wang H, Xing L, Wu Y, Liu H, Qu W, Shao Z
Primary Author: 
Fu R
Journal Title: 
Medicine (Baltimore)
Original Publication Date: 
Feb 2017

We aimed to investigate the efficacy and safety of de-escalation empirical therapy for controlling infection in patients with severe aplastic anaemia (SAA) treated with

Bone Marrow Diseases: